Cell Line Development: Accelerating Antibody Discovery by Monitoring Titer and Glycosylation with the Octet Platform
White Paper Nov 01, 2019
The time it takes from engineering an optimal cell line to the production of the target antibody can be prohibitive.
While expression level analysis is carried out early, other critical quality attributes are often assessed only later in the development process, due to a lack of appropriate and high-throughput analytical techniques. Furthermore, commonly used methods for antibody quantitation require either specialized instrumentation or are time-consuming.
In this whitepaper, find out how you can use new technology to resolve these challenges and:
- Reduce antibody development times
- Save FTE costs
- Perform more projects
Related White Papers
Life science R&D is developing incredible solutions to global problems. But this ground breaking work is often being done with outdated tools that weren't designed with the complexity of life science in mind. Let's explore the core questions that R&D organizations are struggling to answer.READ MORE